摘要
目的研究磺达肝葵钠用于治疗下肢术后深静脉血栓栓塞的临床疗效。方法选取2013年1月~2015年5月天津市第三中心医院分院收治的下肢手术患者83例,随机分为实验组（42例）和对照组（41例）,实验组给予腹部皮下注射磺达肝葵钠（2.5 mg,1次/天,连续给药5天）,对照组口服利伐沙班（10 mg,1次/天,连续服用5天）,于实验开始前、开始后7天及手术后1个月,对所有患者行下肢多普勒超声检查,统计患者包括近端血栓、远端血栓及全静脉血栓在内的深静脉血栓的发生情况,并记录患者于实验期间和术后1个月内,不良反应（皮下出血）的发生情况。结果实验组出现1例（2.38%）深静脉血栓,与对照组的7例（17.07%）深静脉血栓相比,差异具有统计学意义（P〈0.05）;实验组无一例患者出现皮下出血不良反应,对照组出现皮下出血不良反应2例（P〈0.05）。结论磺达肝葵钠预防下肢术后深静脉血栓的临床效果显著优于利伐沙班,且致皮下出血的不良反应显著低于利伐沙班,对下肢术后深静脉血栓的临床预防作用安全有效。
Objective To study the clinical efficacy of fondaparinux sodium in the treat of deep vein thromboembolism after the surgery on lower limbs. Methods 83 cases of patients with lower extremity surgery from Jan 2013 to May 2015,were randomly divided into experimental group（ 42 cases）and control group（ 41 cases）,the patients in experimental group were injected subcutaneously with fondaparinux sodium 2. 5 mg,one time a day,for five days and the patients of control group administrated orally with rivaroxaban 10 mg,one time a day,for five days. All patients accepted the ultrasonic examination by Doppler＇s method before the experiment,seven days and one month later after the experiment. The occurrence of deep vein thromboembolism of all patients was counted,including Proximal thrombosis,Distal thrombosis and Total venous thrombosis,and recorded the occurrence of adverse reaction-subcutaneous hemorrhage. Results One case（ 2. 38%） of deep vein thrombosis was appeared in the experimental group,and that was significantly lower than that of the control group seven case（ 17. 07%,p〈0. 05）. Meanwhile,there was no patient observed adverse reaction in experimental group,while two cases were observed in control group（ p〈0. 05）. Conclusion Fondaparinux showed better clinical efficacy than rivaoxaban,and caused fewer adverse reaction. We can conclude that it is safe and effective for the treatment of deep vein thrombosis in patients accepting the lower limbs surgery.
出处
《中国生化药物杂志》
CAS
2016年第8期68-70,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
深静脉血栓
磺达肝葵钠
利伐沙班
deep vein thromboembosis
fondaparinux sodium
rivaroxaban
